Outcomes with conversion from calcineurin inhibitors to sirolimus after renal transplantation in the context of steroid withdrawal or steroid continuation

Transplantation

Volumn 88, Issue 5, 2009, Pages 684-692

  Egbuna, Ogo I ^a   Davis, Roger B ^a   Chudinski, Robyn ^a   Pavlakis, Martha ^a   Rogers, Christin ^a   Molakatalla, Phani ^a   Johnson, Scott R ^a   Karp, Seth ^a   Monaco, Anthony P ^a   Tang, Hongying ^a   Hanto, Douglas W ^a   Mandelbrot, Didier A ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

Calcineurin inhibitor toxicity; Graft function; Sirolimus

Indexed keywords

CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; CALCINEURIN; DRUG DERIVATIVE; IMMUNOSUPPRESSIVE AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BONE PAIN; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EDEMA; FEMALE; GLOMERULUS FILTRATION RATE; HIGH RISK PATIENT; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY FUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LUNG DISEASE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEINURIA; RISK BENEFIT ANALYSIS; SKIN MANIFESTATION; THROMBOCYTOPENIA; THROMBOSIS; TREATMENT OUTCOME; ULCER; WOUND HEALING IMPAIRMENT; ADOLESCENT; CHILD; DRUG ANTAGONISM; INFANT; METHODOLOGY; MIDDLE AGED; NEWBORN; PRESCHOOL CHILD;

ADOLESCENT; ADULT; AGED; ANTILYMPHOCYTE SERUM; CALCINEURIN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INFANT, NEWBORN; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; SIROLIMUS; STEROIDS; TREATMENT OUTCOME;

EID: 70349561259     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/TP.0b013e3181b27d44     Document Type: Article

References (35)

1. 1. Serkova N, Christians U. Transplantation: Toxicokinetics and mechanisms of toxicity of cyclosporine and macrolides. Curr Opin Investig Drugs 2003; 4: 1287. (Pubitemid 38100573)
2. Davies DR, Bittmann I, Pardo J. Histopathology of calcineurin inhibitorinduced nephrotoxicity. Transplantation 2000; 69: SS11.
3. Nankivell BJ, Borrows RJ, Fung CL, et al. Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 2004; 78: 557.
4. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003; 349: 931.
5. 5. Mota A, Arias M, Taskinen EI, et al. Sirolimus-based therapy following early cyclosporine withdrawal provides significantly improved renal histology and function at 3 years. Am J Transplant 2004; 4: 953. (Pubitemid 38745595)
6. 6. Gurkan AS, Kacar S, Erdogdu U, et al. The effect of sirolimus in the development of chronic allograft nephropathy. Transplant Proc 2008; 40:114. (Pubitemid 351186606)
7. Pontrelli P, Rossini. M, Infante B, et al. Rapamycin inhibits PAI-1 expression and reduces interstitial fibrosis and glomerulosclerosis in chronic allograft nephropathy. Transplantation 2008; 85: 125.
8. 8. Liu M, Zhang W, Gu M, et al. Protective effects of sirolimus by attenuating connective tissue growth factor expression in human chronic allograft nephropathy. Transplant Proc 2007; 39: 1410. (Pubitemid 46907945)
9. 9. Flechner SM, Kurian SM, Solez K, et al. De novo kidney transplantation without use of calcineurin inhibitors preserves renal, structure and function at two years. Am J Transplant 2004; 4: 1776. (Pubitemid 39434437)
10. Dean PG, Lund WJ, Larson TS, et al. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555.
11. 11. Kreis H, Cisterně JM, Land W, et al. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252. (Pubitemid 30238708)
12. 12. McTaggart RA, Gottlieb D, Brooks J, et al. Sirolimus prolongs recovery from, delayed graft function after cadaveric renal transplantation. Am J Transplant 2003; 3: 416. (Pubitemid 36560092)
13. 13. Diekmann F, Budde K, Oppenheimer F, et al. Predictors of success in conversion from calcineurin inhibitor to sirolimus in chronic allograft dysfunction. Am J Transplant 2004; 4: 1869. (Pubitemid 39434449)
14. 14. Watson CJ, Firth J, Williams PF, et al. A randomized controlled trial of late conversion from CNI-based to sirolimus-based immunosuppression following renal transplantation. Am J Transplant 2005; 5: 2496. (Pubitemid 43919435)
15. 15. Peddi VR, Jensik S, Pescovitz M, et al. An open-label, pilot study evaluating the safety and efficacy of converting from calcineurin inhibitors to sirolimus in established renal allograft recipients with moderate renal insufficiency. Clin Transplant 2005; 19: 130. (Pubitemid 40227864)
16. 16. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction, after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005; 20: 2517. (Pubitemid 41548881)
17. 17. Stallone G, Infante B, Schena A, et al. Rapamycin for treatment of chronic allograft nephropathy in renal transplant patients. J Am Soc Nephrol 2005; 16: 3755. (Pubitemid 46211299)
18. 18. Wali RK, Mohanlal V, Ramos E, et al. Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction. Am J Transplant 2007; 7: 1572. (Pubitemid 46776263)
19. Schena FP, Pascoe MD, Alberu J, et al. Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial. Transplantation 2009; 87: 233.
20. 20. Mulay AV, Cockfield S, Stryker R, et al. Conversion from calcineurin inhibitors to sirolimus for chronic renal allograft dysfunction: A systematic review of the evidence. Transplantation 2006; 82: 1153. (Pubitemid 44748017)
21. 21. Khwaja K, Asolati. M, Harmon JV, et al. Rapid discontinuation of prednisone in higher-risk kidney transplant recipients. Transplantation 2004; 78: 1397. (Pubitemid 39507982)
22. 22. Wlodarczyk Z, Walaszewski J, Perner F, et al. Steroid withdrawal at 3 months after kidney transplantation: A comparison of two tacrolimusbased regimens. Transpl hit 2005; 18:157. (Pubitemid 41743305)
23. Woodle ES, First MR, Pirsch J, et al. A prospective, randomized, double-blind, placebo-controlled multicenter trial comparing early (7 day) corticosteroid cessation, versus long-term, low-dose corticosteroid therapy. Ann Surg 2008; 248: 564.
24. 2007. OPTN/SRTR Annual data report. Available at: http://www. ustransplant.org/annual-reports/current/506c-ki.htm; Accessed November 6, 2007.
25. Gaber AO, Kahan BD, Van Buren C, et al; Sirolimus High-Risk Study Group. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: Results from an open-label, randomized trial. Transplantation 2008; 86: 1187.
26. 26. Lo A, Egidi MF, Gaber LW, et al. Comparison of sirolimus-based calcineurin inhibitor-sparing and calcineurin inhibitor-free regimens in cadaveric renal transplantation. Transplantation 2004; 77: 1228. (Pubitemid 38580302)
27. 27. Buchler M, Caillard S, Barbier S, et al; Spiesser Group. Sirolimus versus cyclosporine in kidney recipients receiving thymoglobulin, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007; 7: 2522. (Pubitemid 47561618)
28. 28. Stephany BR, Augustine JJ, Krishnamurthi V, et al. Differences in proteinuria and graft function in de novo sirolimus-based vs. calcineurin inhibitor-based immunosuppression in live donor kidney transplantation. Transplantation 2006; 82: 368. (Pubitemid 44223036)
29. 29. Boratynska M, Banasik M, Watorek E, et al. Conversion to sirolimus from cyclosporine may induce nephrotic proteinuria and progressive deterioration of renal function in chronic allograft nephropathy patients. Transplant Proc 2006; 38: 101. (Pubitemid 43303609)
30. van den Akker JM, Wetzels JF, Hoitsma AJ. Proteinuria following conversion from azathioprine to sirolimus in renal transplant recipients. Kidney Int 2006; 70: 1357.
31. 31. Flechner SM, Goldfarb D, Solez K, et al. Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs. Transplantation 2007; 83: 883. (Pubitemid 46682728)
32. 32. Ekberg H, Tedesco-Silva H, Demirbas A, et al. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562. (Pubitemid 350294223)
33. Smith MP, Newstead CG, Ahmad N, et al. Poor tolerance of sirolimus in a steroid avoidance regimen for renal transplantation. Transplantation 2008; 85: 636.
34. 34. Mulay AV, Hussain N, Fergusson D, et al. Calcineurin inhibitor withdrawal from sirolimus-based therapy in kidney transplantation: A systematic review of randomized trials. Am J Transplant 2005; 5: 1748. (Pubitemid 40910459)
35. 35. Chuang P, Langone AJ. Clobetasol ameliorates aphthous ulceration in renal transplant patients on sirolimus. Am J Transplant 2007; 7: 714. (Pubitemid 46376460)